WO2002043759A3 - Method and composition for modulating bone growth - Google Patents

Method and composition for modulating bone growth Download PDF

Info

Publication number
WO2002043759A3
WO2002043759A3 PCT/US2001/046291 US0146291W WO0243759A3 WO 2002043759 A3 WO2002043759 A3 WO 2002043759A3 US 0146291 W US0146291 W US 0146291W WO 0243759 A3 WO0243759 A3 WO 0243759A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
compositions
bone growth
modulating bone
methods
Prior art date
Application number
PCT/US2001/046291
Other languages
French (fr)
Other versions
WO2002043759A2 (en
Inventor
Karen M Lyons
Vicki Rosen
Aaron Daluiski
Thomas Engstrand
Mathew F Bahamonde
Laura W Gamer
Eric Agius
Karen Cox
Original Assignee
Wyeth Corp
Univ California
Karen M Lyons
Vicki Rosen
Aaron Daluiski
Thomas Engstrand
Mathew F Bahamonde
Laura W Gamer
Eric Agius
Karen Cox
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp, Univ California, Karen M Lyons, Vicki Rosen, Aaron Daluiski, Thomas Engstrand, Mathew F Bahamonde, Laura W Gamer, Eric Agius, Karen Cox filed Critical Wyeth Corp
Priority to AU2002236558A priority Critical patent/AU2002236558A1/en
Priority to EP01986092A priority patent/EP1370287A2/en
Publication of WO2002043759A2 publication Critical patent/WO2002043759A2/en
Publication of WO2002043759A3 publication Critical patent/WO2002043759A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods and compositions are provided for the treatment of defects and disease involving osteoporosis, or osteopenic conditions. The methods comprises applying to the site of osteoporotic or osteopenic conditions a composition comprising a BMP-3 inhibitor or antagonist. The invention further provides methods and compositions for modulating or regulating the formation of bone utilizing BMP-3 compositions.
PCT/US2001/046291 2000-12-01 2001-12-03 Method and composition for modulating bone growth WO2002043759A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002236558A AU2002236558A1 (en) 2000-12-01 2001-12-03 Method and composition for modulating bone growth
EP01986092A EP1370287A2 (en) 2000-12-01 2001-12-03 Method and composition for modulating bone growth

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25053500P 2000-12-01 2000-12-01
US60/250,535 2000-12-01

Publications (2)

Publication Number Publication Date
WO2002043759A2 WO2002043759A2 (en) 2002-06-06
WO2002043759A3 true WO2002043759A3 (en) 2003-10-09

Family

ID=22948150

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/046291 WO2002043759A2 (en) 2000-12-01 2001-12-03 Method and composition for modulating bone growth

Country Status (3)

Country Link
EP (1) EP1370287A2 (en)
AU (1) AU2002236558A1 (en)
WO (1) WO2002043759A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9572865B2 (en) 2005-11-23 2017-02-21 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating multiple myeloma

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5906827A (en) † 1994-06-03 1999-05-25 Creative Biomolecules, Inc. Matrix for the manufacture of autogenous replacement body parts
EP0957943B2 (en) † 1997-02-07 2008-11-26 Stryker Corporation Matrix-free osteogenic devices, implants and methods of use thereof
PT1223990E (en) 1999-10-15 2004-12-31 Fidia Advanced Biopolymers Srl HYALURONIC ACID FORMULATIONS FOR ADMINISTRATION OF OSTEOGENIC PROTEINS
EP1732589A2 (en) * 2004-03-26 2006-12-20 Acceleron Pharma Inc. Bmp-3 propeptides and related methods
WO2005113590A2 (en) 2004-05-12 2005-12-01 Acceleron Pharma Inc. Bmp10 propeptides and related methods
CA2572330A1 (en) 2004-06-24 2006-01-05 Acceleron Pharma Inc. Gdf3 propeptides and related methods
DK2332977T3 (en) 2004-07-23 2016-02-29 Acceleron Pharma Inc ActRII receptor polypeptides
US20060115462A1 (en) * 2004-12-01 2006-06-01 Vladimir Subbotin Direct DNA delivery to bone cells
US7851435B2 (en) 2005-05-27 2010-12-14 Bbs-Bioactive Bone Substitutes Oy Bone morphogenetic protein 3 and osteogenic devices and pharmaceutical products containing thereof
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
EP3811965A1 (en) 2005-11-23 2021-04-28 Acceleron Pharma, Inc. Activin-actriia antagonists in use for promoting bone growth
WO2007123896A2 (en) 2006-04-18 2007-11-01 The Trustees Of The University Of Pennsylvania Mutated acvr1 for diagnosis and treatment of fibrodyplasia ossificans progressiva (fop)
ME02335B (en) 2006-12-18 2013-04-30 Acceleron Pharma Inc Activin-actrii antagonists and uses for treating anemia
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
ES2415666T3 (en) 2007-02-01 2013-07-26 Acceleron Pharma, Inc. Pharmaceutical compositions comprising Activin-ActRIIa antagonists for use in the prevention or treatment of breast cancer metastases or bone loss related to breast cancer
TW202104248A (en) 2007-02-02 2021-02-01 美商艾瑟勒朗法瑪公司 Variants derived from actriib and uses therefor
EP2207562B1 (en) 2007-09-18 2017-05-31 Acceleron Pharma, Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
PL2340031T4 (en) 2008-08-14 2020-12-28 Acceleron Pharma Inc. Gdf traps for use to treat anemia
WO2010083034A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
MX355042B (en) 2009-06-08 2018-04-02 Acceleon Pharma Inc Methods for increasing thermogenic adipocytes.
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc Truncated actriib-fc fusion proteins
CA2781152A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
WO2012064771A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma, Inc. Actriia binding agents and uses thereof
ES2884095T3 (en) 2012-11-02 2021-12-10 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
CN114699529A (en) 2014-06-13 2022-07-05 阿塞勒隆制药公司 Methods and compositions for treating ulcers
MA41052A (en) 2014-10-09 2017-08-15 Celgene Corp TREATMENT OF CARDIOVASCULAR DISEASE USING ACTRII LIGAND TRAPS
SI3227675T1 (en) 2014-12-03 2023-07-31 Celgene Corporation Activin-actrii antagonists and uses for treating myelodysplastic syndrome
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116738A (en) * 1986-07-01 1992-05-26 Genetics Institute, Inc. DNA sequences encoding
US5393739A (en) * 1990-11-30 1995-02-28 Celtrix Pharmaceuticals, Inc. Use of bone morphogenetic protein in synergistic combination with TGF-β for bone repair

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116738A (en) * 1986-07-01 1992-05-26 Genetics Institute, Inc. DNA sequences encoding
US5393739A (en) * 1990-11-30 1995-02-28 Celtrix Pharmaceuticals, Inc. Use of bone morphogenetic protein in synergistic combination with TGF-β for bone repair

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FAUCHEUX C ET AL: "Effect of 1,25(OH)2D3 on bone morphogenetic protein-3 mRNA expression.", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 73, no. 1, 1 April 1999 (1999-04-01), pages 11 - 19, XP002224340, ISSN: 0730-2312 *
FAUCHEUX C ET AL: "Opposing actions of BMP3 and TGFbeta1 in human bone marrow stromal cell growth and differentiation.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 241, no. 3, 29 December 1997 (1997-12-29), pages 787 - 793, XP002224339, ISSN: 0006-291X *
See also references of EP1370287A2 *
THOMADAKIS GEORGIOS ET AL: "Immunolocalization of Bone Morphogenetic Protein-2 and -3 and Osteogenic Protein-1 during murine tooth root morphogenesis and in other craniofacial structures.", EUROPEAN JOURNAL OF ORAL SCIENCES, vol. 107, no. 5, October 1999 (1999-10-01), pages 368 - 377, XP001127481, ISSN: 0909-8836 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9572865B2 (en) 2005-11-23 2017-02-21 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating multiple myeloma

Also Published As

Publication number Publication date
EP1370287A2 (en) 2003-12-17
WO2002043759A2 (en) 2002-06-06
AU2002236558A1 (en) 2002-06-11

Similar Documents

Publication Publication Date Title
WO2002043759A3 (en) Method and composition for modulating bone growth
EP0911321A3 (en) Compounds for the treatment of osteoporosis
YU18400A (en) Prostaglandin agonists and their use to treat bone disorders
HUP0500634A2 (en) Materials and methods to promote repair of nerve tissue
DE69936102D1 (en) USE OF TNF-ALPHA INHIBITORS FOR THE TREATMENT OF NERVE ROOT DAMAGE
MY141384A (en) Prevention of loss and restoration of bone mass by certain prostaglandin agonists
WO1998058911A3 (en) Prostaglandin agonists
NO20075801L (en) Method of treating or preventing bone destruction or osteoporosis
WO2005037259A3 (en) Methods and compositions for the prevention or treatment of neoplasia comprising a cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
WO2005053795A3 (en) Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
WO2005094871A3 (en) Bmp-3 propeptides and related methods
WO2002010348A3 (en) Tissue implant for cartilage repair
WO2006039400A3 (en) Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis
ATE492275T1 (en) VITAMIN K FOR PREVENTING AND TREATING SKIN RASH AS A RESULT OF ANTI-EGFR THERAPY
AU2003211140A1 (en) Composition and method for inducing bone growth and healing
AU2002258592A1 (en) Compositions and methods for modulating bone mineral deposition
EP1205189A3 (en) Combination of a prostaglandin agonist and a HMG-CoA reductase inhibitor for the stimulation of bone growth
ATE394124T1 (en) METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR MODULATING BONE GROWTH
WO2004064832A3 (en) Methods for treating joint pain or improving sleep using an estrogen agonist/antagonist
AU2003233735A1 (en) 24-sulfoximine vitamin d3 compounds
WO2004006833A3 (en) Bowel cleansing composition
WO2004032908A3 (en) Method of inhibiting angiogenesis
WO2003034987A3 (en) Androgen receptor modulators and methods of use thereof
GB2404198A (en) Methods for treating deodorizer distillate
DE60143034D1 (en) OPTICALLY PURE (-) CLETHODIM, AS WELL AS THESE COMPOSITIONS AND METHOD FOR CONTROLLING PLANT GROWTH

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001986092

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001986092

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP